Reviews/Rheumatoid Arthritis Targeted Therapy/Interleukin-6 receptor inhibitors achieve responses in rheumatoid arthritis, tocilizumab superior to adalimumab
Non TNF Biologics · RA-IL6-01 · v2
Borderline: within 4 points of the Likely/Uncertain boundary, so a re-grade could land either side.
This claim has two parts: that drugs blocking the interleukin-6 receptor produce strong joint-symptom responses, and that one such drug, tocilizumab, does better than the older drug adalimumab when each is used on its own. A direct head-to-head trial [3] shows a related IL-6 receptor drug, sarilumab, reaching the ACR50 response benchmark and beating adalimumab. For tocilizumab specifically, the corpus offers cost-per-response and cost-effectiveness analyses [1][2][6] that consistently favour it over adalimumab, but these report money-per-responder rather than a clean head-to-head efficacy comparison. No paper in the corpus measures the ACR50 benchmark for an IL-6 receptor drug given together with methotrexate. The panel therefore accepted that these drugs achieve ACR50 and that tocilizumab looks better than adalimumab, while noting the tocilizumab evidence is indirect and the methotrexate part is unsupported.
A primary randomised head-to-head trial [3] shows sarilumab monotherapy achieving ACR20/50/70 of 71.7%/45.7%/23.4% versus adalimumab 58.4%/29.7%/11.9% (all p≤0.0074), establishing that an IL-6R inhibitor monotherapy reaches ACR50 and beats adalimumab. For tocilizumab, ADACTA-derived cost-per-response data [1] reports ACR50 cost-per-response of $38,720 for tocilizumab versus $92,244 for adalimumab, a gap corroborated by an economic evaluation [2] finding tocilizumab "more effective" than adalimumab. Sarilumab economic modelling [5] similarly reports ACR50 cost-per-responder of $41,475 versus $98,425 for adalimumab. A further Markov model [6] finds tocilizumab more cost-effective than adalimumab. None of these tocilizumab papers is a primary efficacy publication reporting head-to-head ACR50 rates with confidence intervals. The contested point: The evidence divides on whether tocilizumab-specific superiority is genuinely demonstrated: the only primary head-to-head RCT in the corpus [3] is sarilumab, and the tocilizumab case rests on cost-effectiveness re-analyses [1][2][6] that report cost-per-responder rather than efficacy statistics. It also divides on the methotrexate-combination clause, for which no corpus paper reports ACR50.
All 15 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Rheumatoid Arthritis Targeted Therapy, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The primary ADACTA efficacy publication is absent; the tocilizumab-superiority half rests on cost-effectiveness re-analyses ([1][2][6]) reporting cost-per-response, not head-to-head efficacy statistics with confidence intervals.
The only direct primary RCT of IL-6R inhibitor superiority over adalimumab in the corpus ([3] MONARCH) uses sarilumab, not tocilizumab; using it to support 'tocilizumab superior' is a within-class drug substitution.
Where it remains uncertain. Tocilizumab-specific superiority leans on cost-effectiveness re-analyses [1][2][6] rather than a primary efficacy paper, and no corpus paper [8] quantifies ACR50 for an IL-6R inhibitor combined with methotrexate.
Aleatory
The head-to-head evidence comes from single trials of a few hundred patients ([3] N=369; [1] N=325), so response-rate estimates carry sampling variability.
Epistemic
The corpus contains no primary efficacy publication reporting tocilizumab-versus-adalimumab ACR50 rates with confidence intervals; the ADACTA source trial's efficacy paper is absent.
Inferential
The claim names tocilizumab, but the direct primary superiority RCT [3] is sarilumab; supporting the tocilizumab claim requires inferring across the drug class.
The load-bearing papers from a corpus of 15, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
ADACTA-derived data showing tocilizumab achieves ACR50 at less than half the cost per responder of adalimumab, implying a higher tocilizumab ACR50 response rate.
“Mean drug and administration costs per each clinical response achieved were lower with TCZ than with ADA (DAS28 < 2.6: $45,868 vs $244,174; ACR20: $28,127 vs $51,887; ACR50: $38,720 vs $92,244; ACR70: $56,253 vs $143,136)”
Panel auditInternal validity: low · scope of inference: Comparative drug and adverse-event costs per clinical response for TCZ vs ADA monotherapy over 24 weeks in RA.Key limitations: cost outcome not efficacy · ACR50 rates not stated · response proportions not reported
Economic re-analysis of ADACTA corroborating that tocilizumab is more effective than adalimumab monotherapy.
“Compared with ADA, TCZ was more effective, with an estimated 6-month incremental cost ranging from $6,570 per additional low disease activity score achiever to $14,265 per additional ACR 70% improvement criteria responder.”
Panel auditInternal validity: low · scope of inference: Cost-effectiveness of TCZ vs ADA monotherapy in RA patients for whom methotrexate is inappropriate, US payer perspective.Key limitations: modelled not measured · effectiveness from one trial · no ACR50 rate reported
Primary RCT evidence that an IL-6R inhibitor monotherapy achieves ACR50 (45.7%) and is superior to adalimumab monotherapy (29.7%).
“Sarilumab-treated patients achieved significantly higher American College of Rheumatology 20/50/70 response rates (sarilumab: 71.7%/45.7%/23.4%; adalimumab: 58.4%/29.7%/11.9%; all p≤0.0074)”
Panel auditInternal validity: high · scope of inference: Sarilumab vs adalimumab monotherapy in RA patients unable to continue methotrexate.Key limitations: drug is sarilumab not tocilizumab · MTX-intolerant/inadequate-responder population · 24-week horizon
Supports class-level IL-6R (sarilumab) ACR50 achievement and superiority over adalimumab monotherapy.
“24-week drug costs were $18,954 and $29,232, and costs per responder were $26,435 vs $50,055 on ACR20; $41,475 vs $98,425 on ACR50”
Panel auditInternal validity: low · scope of inference: Cost per effectively treated patient for sarilumab vs adalimumab monotherapy in moderately-to-severely active RA, US payer perspective.Key limitations: modelled not measured · drug is sarilumab not tocilizumab · efficacy from single trials
4 of 15 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Both directional halves are supported and no corpus evidence contradicts them, but the reliance on economic re-analyses for the tocilizumab head-to-head and the unsupported methotrexate clause keep it below the Established band.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Primary tocilizumab-vs-adalimumab ACR50 efficacy paper. The tocilizumab-superiority half rests on economic re-analyses rather than a primary efficacy publication reporting ACR50 rates directly. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: Include the ADACTA primary efficacy publication reporting head-to-head ACR50 response rates with confidence intervals for tocilizumab versus adalimumab monotherapy.
Open question: Does tocilizumab monotherapy achieve a higher ACR50 response rate than adalimumab monotherapy in a direct efficacy comparison? Why it is still open: The corpus carries tocilizumab superiority only through cost-per-response and cost-effectiveness analyses [1][2][6], not a primary efficacy publication with head-to-head ACR50 rates and confidence intervals.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 18 Sep 2026 · protocol v0.19